Presepsin ve COVID 19: Literatürün gözden geçirilmesi

Yıl 2021, Cilt: 4 Sayı: 2, 69 - 72, 08.08.2021

Sevil Alkan , Emel Yıldız , Havva Yasemin Çinpolat , Serpil Oğuz Mızrakçı

https://doi.org/10.33713/egetbd.950007

Cited By: 1

Öz

Günümüzde hakkında global olarak çok sayıda araştırmalar devam eden Koronavirüs hastalığı (COVID-19) hastalığının da prognozunun belirlenmesinde, patolofizyolojisinin anlaşılmasında biyobelirteçlerin rol alabileceği düşünülmektedir. Presepsin de bu biyobelirteçlerden olup, kritik COVID-19 vakalarının erken tespitinde ve mortalite riskinin değerlendirmesinde kullanılabileceği iddia edilmiştir. Biz de çalışmamızda Koronavirüs COVID-19 ve presepsin ilişkisini literatür eşliğinde irdelemeyi amaçladık. Sınırlı sayıdaki bilimsel makale mevcut olup, mevcut veriler kısıtlı hasta sayılarını içermektedir. Sonuç olarak presepsinin COVID 19 da kullanılabilecek bir biyomarker olduğu konusunda henüz kesin bilimsel kanıtlar bulunmamaktadır. Daha fazla hastayı içerem ileriye dönük çalışmalara ihtiyaç duyulmaktadır.

Anahtar Kelimeler

COVID 19, biyomarker, presepsin

Destekleyen Kurum

yok

Proje Numarası

yok

Kaynakça

• 1. Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med. 2014;5(1):16-9.
• 2. Meuleman P, Steyaert S, Libbrecht L, Couvent S, Van Houtte F, Clinckspoor F, et al. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. Clin Chim Acta. 2006; 366:156–62.
• 3. Su GL, Dorko K, Strom SC, Nüssler AK, Wang SC. CD14 expression and production by human hepatocytes. J Hepatol. 1999;31:435–42.
• 4. Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide-binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011; 24 suppl 2:12–4.
• 5. Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005; 11:234–8.
• 6. Gong XW, Jiang Y. Structure, function and modulation of actin-related protein 2/3 complex. Sheng Li Ke Xue Jin Zhan. 2004;35:306–10.
• 7. Yin K, Dang SC, Zhang JX. Relationship between expression of triggering receptor-1 on myeloid cells in intestinal tissue and intestinal barrier dysfunction in severe acute pancreatitis. World J Emerg Med. 2011;2:216–221.
• 8. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of perception in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012;18:891–897.
• 9. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS) Hypertens Res. 2008;31:2115–2127.
• 10. Zhang J, Hu ZD, Song J, Shao J. Diagnostic Value of Presepsin for Sepsis: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94(47):e2158.
• 11. Zhang S, Lin Q‐H, Shen L‐H, et al. Diagnostic value and prognostic evaluation of presepsin for acute respiratory distress syndrome (ARDS). Fudan Univ J Med Sci. 2019; 46:357‐ 365.
• 12. Arslan B, Sepici Dinçel A. Biyokimya laboratuvarında COVID-19: Klinik araştırmadan rutine enflamatuvar belirteçler. Yücel D, editör. COVID-19 Pandemisinde Tıbbi Biyokimyanın Artan Rolü. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. p.13-8.
• 13. Henry Bm, de Oliveira mH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021-8.
• 14. Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020;507:161-3.
• 15. Tosato F, Giraudo C, Pelloso M, Musso G, Piva E, Plebani M. One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients. Clin Chem Lab Med. 2020;58(7):1149-51.
• 16. Schirinzi A, Cazzolla AP, Lovero R, Lo Muzio L, Testa NF, Ciavarella D, et al. New Insights in Laboratory Testing for COVID-19 Patients: Looking for the Role and Predictive Value of Human epididymis secretory protein 4 (HE4) and the Innate Immunity of the Oral Cavity and Respiratory Tract. Microorganisms. 2020;8(11):1718.
• 17. Fukada A, Kitagawa Y, Matsuoka M, Sakai J, Imai K, Tarumoto N, Orihara Y, et al. Presepsin as a predictive biomarker of severity in COVID-19: A case series. J Med Virol. 2021;93(1):99-101.
• 18. Zaninotto M, Mion MM, Cosma C, Rinaldi D, Plebani M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020;507:161-3.
• 19. Dewi R, Kaswandani N, Karyanti MR, Setyanto DB, Pudjiadi AH, Hendarto A, et al. Mortality in children with positive SARS-CoV-2 polymerase chain reaction test: Lessons learned from a tertiary referral hospital in Indonesia. Int J Infect Dis. 2021;107:78-85.
• 20. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131-4.
• 21. Lippi G, Plebani M. The novel coronavirus (2019-nCoV) outbreak: think the unthinkable and be prepared to face the challenge. Diagnosis (Berl) 2020;7:79–81.
• 22. Cervellin G, Schuetz P, Lippi G. Toward a holistic approach for diagnosing sepsis in the emergency department. Adv Clin Chem 2019;92:201–16.
• 23. Lippi G. Sepsis biomarkers: past, present and future. Clin Chem Lab Med 2019;57:1281–3.
• 24. Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012; 18: 891- 7.
• 25. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the albumin Italian outcome sepsis trial. Crit Care. 2014; 18: R6.